viewAvacta Group PLC

Full interview: Avacta Group PLC boss sees a huge opportunity with new version of cancer treatment

Alastair Smith, Avacta Group PLC’s (LON:AVCT) chief executive, believes it has huge opportunities for a new version of cancer treatment Doxorubicin using the technology it licensed from Tufts University.
Doxorubicin has been a standard treatment for soft tissue cancers for decades, but heart toxicity issues limit its use.
Smith believes that Avacta’s Pro-Doxorubicin can eliminate many of these problems because it is inert until it gets inside a tumour.
Takeaway the side effects and Pro-Doxorubicin can be anything between a US$2-5bn a year drug, he told Proactive.
"If we see the same improvement as we have seen in animals there is a huge commercial opportunity," especially as the safety profile of fourteen other drugs might potentially be enhanced through Tufts technology.
Data from a phase 1 trial is scheduled for 12 months, by which time Avacta wants term sheets in place for a licensing deal that might immediately bring a US$50mln upfront payment.
That would be a genuinely transformational amount of non-diluting capital for the business, Smith says.

Quick facts: Avacta Group PLC

Price: 148 GBX

Market: AIM
Market Cap: £368.75 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Avacta Group PLC named herein, including the promotion by the Company of Avacta Group PLC in any Content on the Site, the Company receives from...



Avacta Plc's therapeutics business 'has huge amount of potential' - analyst...

Capital Network analyst Ed Stacey discusses the major value driver for Avacta - the development of its proprietary Affimer technology for therapeutics, particularly in the immune-oncology (I-O) space. The group's reported interim results to January 2019 today, revealing revenues of...

on 9/4/19

2 min read